Leukemia News and Research

RSS

Leukemia (Leukaemia) is a cancer of the blood cells. It is the most common type of blood cancer and affects 10 times as many adults as children. Most people diagnosed with leukemia are over 50 years old. No one knows why some people develop leukemia and others do not. However, scientists have identified some risk factors for the disease. Most people who have known risk factors do not get leukemia, while many who do get the disease have none of these risk factors. During the early stages of leukemia, there may be no symptoms. Many of the symptoms of leukemia don't become apparent until a large number of normal blood cells are crowded out by leukemia cells.

Scientists Kill Cancer Cells By 'Shutting The Door' To The Nucleus

Scientists have shown that blocking the construction of nuclear pores complexes shrank aggressive tumors in mice while leaving healthy cells unharmed.

29 Sep 2020

Researchers identify new way to treat chronic myelogenous leukemia

Scientists have detected a second path to treat chronic myelogenous leukemia, which is known to affect older adults, despite its resistance to drugs.

22 Sep 2020

SMART researchers discover a novel method to produce human red blood cells

Researchers from Singapore-MIT Alliance for Research and Technology (SMART), MIT's research enterprise in Singapore, have discovered a new way to manufacture human red blood cells (RBCs) that cuts the culture time by half compared to existing methods and uses novel sorting and purification methods that are faster, more precise and less costly.

15 Sep 2020

Inherited variation in GATA3 gene associated with relapse in children with leukemia

Scientists at St. Jude Children's Research Hospital are investigating the inherited genetics of childhood leukemia and how particular gene variations can affect treatment outcomes. The research showed that an inherited variation in the GATA3 gene strongly influences early response to chemotherapy and is linked to relapse in children with acute lymphoblastic leukemia (ALL).

14 Sep 2020

Eliminating tumors with engineered ‘off-the-shelf’ therapeutic T cells

Personalized cancer treatments are no longer just options of the future. In the past few years, researchers have made significant progress in 'teaching' the body's immune T cells to recognize and kill specific cancer cells, and human clinical trials have shown that this approach can successfully eliminate tumors

21 Aug 2020

A genetic link discovered to predict treatment response for patients with rare, aggressive cancer

A Singapore team led by clinician-scientists and researchers from the National Cancer Centre Singapore (NCCS) discovered a genetic link to better predict treatment response for relapsed/refractory patients with natural- killer T-cell lymphoma (NKTCL), a highly aggressive form of blood cancer.

13 Aug 2020

Combination regimen improves overall survival in acute myeloid leukemia patients

A combination regimen of venetoclax and azacitidine was safe and improved overall survival (OS) over azacitidine alone in certain patients with acute myeloid leukemia (AML), according to the Phase III VIALE-A trial led by The University of Texas MD Anderson Cancer Center.

13 Aug 2020

Study indicates a powerful treatment for pulmonary fibrosis

A pre-clinical study led by scientists at Cincinnati Children's demonstrates that in mice the drug barasertib reverses the activation of fibroblasts that cause dangerous scar tissue to build up in the lungs of people with idiopathic pulmonary fibrosis (IPF).

7 Aug 2020

Epigenetics key to daily production of 10 billion blood cells without mistakes

Just one in 2,000 bone marrow cells are hematopoietic stem cells (HSC), but these are the source of the ten billion blood cells humans make every day.

6 Aug 2020

Clinical trial shows CAR-T cell therapy can be used for treating Hodgkin lymphoma

CAR-T cell therapy, which attacks cancer cells using a person's reprogrammed immune cells, has been used to treat Hodgkin lymphoma with remarkable success for the first time, according to the results of an early phase clinical trial led by researchers at UNC Lineberger Comprehensive Cancer Center and Baylor College of Medicine in Houston.

24 Jul 2020

New approach is more effective in treating certain blood cancers

Some of the most promising advances in cancer treatment have centered on immunotherapies that rev up a patient's immune system to attack cancer.

24 Jul 2020

Reactivating divergent signaling pathways to enhance cancer treatment

In order for cancer to form in the human body, normal cells must acquire multiple mutations before they develop toward the disease. It was previously believed that these mutations acted in concert in the progression of cancer.

23 Jul 2020

Josep Carreras Institute creates spin-off to develop CAR-T based therapies for leukemia

The Josep Carreras Leukaemia Research Institute, a public centre pertaining to the Generalitat de Catalunya's (Government of Catalonia) CERCA network, has created the OneChain Immunotherapeutics spin-off, the aim of which is to develop new immuno-oncological therapeutic tools with various preclinical candidates, based on CAR-T technology for different tumors, such as cortical T-cell acute lymphoblastic leukemia (coT-ALL), a rare subtype of leukemia that mainly affects children, and which has a poor prognosis.

21 Jul 2020

Rare inherited mutation in TP53 gene predisposes to a wide range of cancers

Rare inherited mutations in the body's master regulator of the DNA repair system – the TP53 gene – can leave people at a higher risk of developing multiple types of cancer over the course of their lives.

17 Jul 2020

Dual inhibitor therapy may be safer for patients with chronic lymphocytic leukemia

Chronic lymphocytic leukemia (CLL) is the most common leukemia in adults. One in four new leukemia cases are CLL.

15 Jul 2020

Researchers explore the reproduction of adenoviruses in cells

An adenovirus infection can be potentially life-threatening, especially for children after a stem cell transplant.

14 Jul 2020

Molecular landscape of myelodysplastic/myeloproliferative neoplasms revealed

Myelodysplastic/myeloproliferative neoplasms (MDS/MPN) is a group of rare malignancies with overlapping features from myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPN), that include a variety of diseases depending on their phenotype (hematological and morphological characteristics).

3 Jul 2020